Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs

Published:2024-05 Issue: Volume:369 Page:179-198
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Tseng Yi-Han,Lin Hsuan-Pei,Lin Sung-Yao,Chen Bing-Mae,Vo Thanh Nguyet Nguyen,Yang Shih-Hung,Lin Yi-Chen,Prijovic Zeljko,Czosseck Andreas,Leu Yu-Lin,Roffler Steve R

Funder

Academia Sinica

National Laboratory Animal Center

Institute of Biomedical Sciences, Academia Sinica

National Science and Technology Council

Publisher

Elsevier BV

Reference73 articles.

1. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives;Solomon;Adv. Drug Deliv. Rev.,2017

2. Arginine-depleting enzymes - an increasingly recognized treatment strategy for therapy refractory malignancies;Riess;Cell. Physiol. Biochem.,2018

3. Use of exogenous enzymes in human therapy: approved drugs and potential applications;Cioni;Curr. Med. Chem.,2022

4. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination;Sharma;Expert. Opin. Biol. Ther.,2017

5. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme;Triplett;Nat. Biotechnol.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP